Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAPDH | P04406 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31131 | 1.00 | GAPDH (0.37) | GAPDHKDM4ETDP1LMNAALOX15 | |
| Lactic Acid SCHEMBL7630269 | 0.90 | TP53 (0.41) | GAPDH | |
| SCHEMBL3868756 | 0.83 | CHRM1 (0.33) | TDP1CA1CA2 | |
| SCHEMBL6055381 | 0.82 | AKR1B1 (0.39) | TDP1LMNAALOX15BLMPMP22 | |
| SCHEMBL1784421 | 0.81 | GAPDH (0.39) | GAPDHTDP1 | |
| SCHEMBL1784419 | 0.81 | GAPDH (0.39) | GAPDHTDP1 | |
| SCHEMBL711050 | 0.79 | GAPDH (0.38) | GAPDH | |
| SCHEMBL11674955 | 0.79 | KDM4E (0.42) | KDM4ETDP1LMNAALOX15BLM | |
| SCHEMBL16667 | 0.79 | GAPDH (0.38) | GAPDH | |
| SCHEMBL3868461 | 0.78 | TRPA1 (0.46) | GAPDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 242 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220403361-A1 | CRYSTALLIZED OXALATE DECARBOXYLASE AND METHODS OF USE | GLYSCEND, INC. | 2022-12-22 | — | — | US | claimed |
| EP-1492554-B1 | SPHERICAL PROTEIN PARTICLES | ALTHEA TECH INC (US) | 2019-08-21 | — | — | EP | claimed |
| US-20150050238-A1 | TREATMENT OF OSTEOARTHRITIS AND PAIN | ABBOTT LABORATORIES | 2015-02-19 | — | — | US | claimed |
| US-8940873-B2 | Crystalline anti-human IL-12 antibodies | ABBVIE INC. (US) | 2015-01-27 | — | — | US | claimed |
| US-8889130-B2 | Treatment of osteoarthritis and pain | ABBVIE INC. (US) | 2014-11-18 | — | — | US | claimed |
| US-8841417-B2 | IL-1 binding proteins | ABBVIE INC. (US) | 2014-09-23 | — | — | US | claimed |
| WO-2014113648-A1 | CRYSTALLIZED OXALATE DECARBOXYLASE AND METHODS OF USE | ALLENA PHARMACEUTICALS, INC. (US) | 2014-07-24 | — | — | WO | claimed |
| US-8772458-B2 | Crystalline anti-hTNFalpha antibodies | ABBVIE BIOTECHNOLOGY LTD (BM) | 2014-07-08 | — | — | US | claimed |
| US-20140086988-A1 | Stabilized Protein Crystals, Formulations Containing Them and Methods of Making Them | ALTHEA TECHNOLOGIES, INC. (US) | 2014-03-27 | — | — | US | claimed |
| WO-2014011955-A2 | IL-1 BINDING PROTEINS | ABBVIE, INC. (US) | 2014-01-16 | — | — | WO | claimed |
| JP-2005500304-A | — | — | 2005-01-06 | — | — | JP | claimed |
| EP-1492554-A2 | SPHERICAL PROTEIN PARTICLES AND METHODS OF MAKING AND USING THEM | Altus Biologics Inc. (US) | 2005-01-05 | — | — | EP | claimed |
| US-20040219224-A1 | Spherical protein particles and methods for making and using them | AJINOMOTO ALTHEA INC. | 2004-11-04 | — | — | US | claimed |
| US-20030175239-A1 | Stabilized protein crystals, formulations comprising them and methods of making them | ALTUS BIOLOGICS INC. | 2003-09-18 | — | — | US | claimed |
| US-20030130189-A1 | P-amidobenzylethers in drug delivery agents | SEAGEN INC. | 2003-07-10 | — | — | US | claimed |
| US-20030096743-A1 | p-Amidobenzylethers in drug delivery agents | SEATTLE GENETICS, INC. | 2003-05-22 | — | — | US | claimed |
| WO-2003026577-A2 | P-AMIDOBENZYLETHERS IN DRUG DELIVERY AGENTS | SEATTLE GENETICS, INC. (US) | 2003-04-03 | — | — | WO | claimed |
| WO-2003000014-A2 | SPHERICAL PROTEIN PARTICLES AND METHODS OF MAKING AND USING THEM | ALTUS BIOLOGICS, INC. (US) | 2003-01-03 | — | — | WO | claimed |
| US-20020136719-A1 | Crystals of whole antibodies and fragments thereof and methods for making and using them | AJINOMOTO ALTHEA INC. | 2002-09-26 | — | — | US | claimed |
| US-20020045582-A1 | STABILIZED PROTEIN CRYSTALS FORMULATIONS CONTAINING THEM AND METHODS OF MAKING THEM | AJINOMOTO ALTHEA INC. | 2002-04-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130189-A1 | P-amidobenzylethers in drug delivery agents | ZYX, LPXN, NPBWR1 | GAPDH 4677/4885KDM4E 3067/4885TDP1 4347/4885 |
| US-20030096743-A1 | p-Amidobenzylethers in drug delivery agents | ZYX, LPXN, NPBWR1 | GAPDH 4728/4885KDM4E 2062/4885TDP1 4590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.